LONDON, Jan 30 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its long-term efficacy ...
Novo Nordisk disclosed top-line data from the phase 3 Redefine 1 study showing 20.4% placebo-adjusted weight loss for obesity drug candidate CagriSema after 68 weeks of treatment, among patients ...
Novo Nordisk is “well placed” to continue to benefit from the high demand for GLP-1 medications in the near-term, and while the CagriSema Phase 3 data in obesity was disappointing, it is still ...
The Street broadly expected the Redefine-1 trial of CagriSema to show ~25% weight loss, raising the benchmark injectables in development. Viking Therapeutics highlighted new clinical data from its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback